Jefferies reiterates Hana at buy

Hana Biosciences Inc. was reiterated by Jefferies & Co., Inc. analyst Adam Walsh at a buy with a reduced price target of $13 from $16. The analyst is recommending buying the stock on any weakness. Near-term Zensana approval should drive shares higher. The company suspended its phase 2 trial of Talvesta in a non-small cell lung cancer trial due to higher-than-expected rates of mucositis/myelosuppression, perhaps due to an aggressive dosing schedule. Shares of the South San Francisco, Calif.-based development-stage biopharmaceutical company were down 35 cents, or 4.65%, at $7.18. (Nasdaq: HNAB)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.